Trial Profile

A Phase I Clinical Trial to Evaluate Tolerance, Pharmacokinetics and Pharmacodynamic of YL-90148 Tablets in Healthy Chinese Subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YL 90148 (Primary)
Indications Gout; Hyperuricaemia
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Sponsors Shanghai Yingli Pharmaceutical

Most Recent Events

31 May 2019 New trial record
19 Nov 2018 According to a Shanghai Yingli Pharmaceutical media release, this trial has been successfully initiated at Shanghai Xuhui District Central Hospital, China.The participating experts and clinical researchers conducted further communication and discussion on the details of the trial protocol, operation procedures and the recruitment of subjects, and reached a consensus.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com